Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study
- PDF / 354,918 Bytes
- 4 Pages / 595.276 x 790.866 pts Page_size
- 48 Downloads / 191 Views
COVID-19
Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study Gloria Dalla Costa 1,2 & Letizia Leocani 1,2 & Xavier Montalban 3 & Ana Isabel Guerrero 3 & Per Soelberg Sørensen 4 & Melinda Magyari 4 & Richard J. B. Dobson 5,6 & Nicholas Cummins 7 & Vaibhav A. Narayan 8 & Matthew Hotopf 9 & Giancarlo Comi 1 & on behalf of the RADAR-CNS consortium Received: 3 June 2020 / Accepted: 16 June 2020 # Fondazione Società Italiana di Neurologia 2020
Abstract We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic. Keywords Multiple Sclerosis . Remote monitoring technologies . COVID-19
Introduction SARS-CoV-2 is a coronavirus first identified in December 2019 in China as the cause of a cluster of pneumonia cases (COVID19 disease) of previously unknown aetiology [1]. The virus has since spread globally, with the World Health Organization (WHO) declaring a pandemic state in March 2020 (https:// www.who.int/emergencies/diseases/novel-coronavirus-2019/
situation-reports). However, the real prevalence and impact of the disease are unknown. Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS) is an Innovative Medicine Initiative-funded project aimed at monitoring major depressive disorders, epilepsy, and multiple sclerosis (MS) using wearable devices and smartphone technology [2]. Through the ongoing remote monitoring of MS patients in
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10072-020-04519-x) contains supplementary material, which is available to authorized users. * Giancarlo Comi [email protected] 1
Institute of Experimental Neurology, IRCCS Ospedale San Raffaele, via Olgettina 60, 20132 Milan, Italy
2
Neurorehabilitation Unit, IRCCS Ospedale San Raffaele, Milan, Italy
3
Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
4
Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
5
The Department of Biostatistics and Health informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
6
Institute of Health Informatics, University College London, London, UK
7
E
Data Loading...
